Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1222 effects on vascular factors in low bone mass
NCT03898024Phase 1Completed
- Sponsor
- The Second Xiangya Hospital
- Start
- Apr 2019
- Primary completion
- Jul 2020
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SHR-1222 in osteopenia and osteoporosis (5 cohorts), sponsored by The Second Xiangya Hospital. Primary endpoints: Serum Nitric Oxide at Day 57, Serum Endothelin-1 at Day 57 and 2 more. Started Apr 2019; status: completed.
02
Drugs
SHR-1222
03
Conditions
osteopeniaosteoporosis
Beyond the preview
Go deeper on NCT03898024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03898024.